Tp53 gene therapy:: a key to modulating resistance to anticancer therapies?

被引：24

作者：

Chang, EH ^{[1
]}

Pirollo, KF ^{[1
]}

Bouker, KB ^{[1
]}

机构：

[1] Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA

来源：

MOLECULAR MEDICINE TODAY | 2000年 / 6卷 / 09期

关键词：

D O I：

10.1016/S1357-4310(00)01767-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Abnormalities in the p53 tumor suppressor have been identified in over 60% of human cancers. The status of p53 within tumor cells has been proposed to be one of the major determinants of the response to anticancer therapies. In this review we examine the relationship between functional p53 and sensitivity, or resistance, to chemotherapy and radiotherapy. We also discuss the potential of current gene-therapy approaches to restore functional p53 to tumors as a means of modulating the effects of radiation and chemotherapy.

引用

页码：358 / 364

页数：7

共 74 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2]

Abarzua P, 1996, ONCOGENE, V13, P2477

[3] Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress [J].

Amundson, SA ;

Myers, TG ;

Fornace, AJ .

ONCOGENE, 1998, 17 (25) :3287-3299

[4] Mechanisms of p53-mediated apoptosis [J].

Bates, S ;

Vousden, KH .

CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :28-37

[5] COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].

BERGH, J ;

NORBERG, T ;

SJOGREN, S ;

LINDGREN, A ;

HOLMBERG, L .

NATURE MEDICINE, 1995, 1 (10) :1029-1034

[6] The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy [J].

Bristow, RG ;

Benchimol, S ;

Hill, RP .

RADIOTHERAPY AND ONCOLOGY, 1996, 40 (03) :197-223

[7] Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].

Bunz, F ;

Hwang, PM ;

Torrance, C ;

Waldman, T ;

Zhang, YG ;

Dillehay, L ;

Williams, J ;

Lengauer, C ;

Kinzler, KW ;

Vogelstein, B .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269

[8]

Calvert AH, 1999, SEMIN ONCOL, V26, P90

[9]

Chang EH, 2000, CANC DRUG DISC DEV, V5, P519

[10]

Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507

← 1 2 3 4 5 6 7 8 →